MRF-Logo2019-Horizontal-RGB
Australian Study – Ipi
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Australian Study – Ipi

› Forums › Ocular Melanoma Community › Australian Study – Ipi

  • Post
    • December 3, 2014 at 2:09 pm
    JerryfromFauq
    Participant

      Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
      CONCLUSION:
      In an Australian clinical practice setting, ipilimumab achieved efficacy and tolerability measures similar to those reported in clinical trials. The frequency and severity of ipilimumab-related AEs (including death) are notable, and treatment should occur under the supervision of an experienced clinical team.
      http://www.ncbi.nlm.nih.gov/pubmed/24999899

    Viewing 2 reply threads
    • Replies
        • December 3, 2014 at 2:21 pm
        JerryfromFauq
        Participant

          Median OS for patients with non-cutaneous (mucosal and uveal) melanomas was almost half that of patients with cutaneous melanoma:

           

          • December 3, 2014 at 2:21 pm
          JerryfromFauq
          Participant

            Median OS for patients with non-cutaneous (mucosal and uveal) melanomas was almost half that of patients with cutaneous melanoma:

             

            • December 3, 2014 at 2:21 pm
            JerryfromFauq
            Participant

              Median OS for patients with non-cutaneous (mucosal and uveal) melanomas was almost half that of patients with cutaneous melanoma:

               

          Viewing 2 reply threads

          Tagged: , ,

          • You must be logged in to reply to this topic.
          About the MRF Patient Forum

          The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

          The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

          Popular Topics